ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/vinca-alkaloid
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/vinca-alkaloid
21
trial(s) found.
NCT06564038
Haem
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies (
Soundtrack-E
)
bispecific T-cell engager,CD19-targeting
+ vinca alkaloid
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Leukaemia
Mantle cell lymphoma
Non-Hodgkin's lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06459180
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (
2870-020
)
anti-Trop2 antibody-drug conjugate
+ vinca alkaloid
Cervical cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06435429
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment (
JZP598-303
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
bispecific ERBB2/ERBB2 antibody
+ vinca alkaloid
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3149 - Mount Waverley - Waverley Private Hospital - Oncology
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06356129
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (
GOLSEEK-1
)
CELMoD agent
placebo
+ vinca alkaloid
Diffuse large B-cell lymphoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT05605899
Haem
Phase 3
Recruiting
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (
ZUMA-23
)
autologous CAR-T-cell therapy,CD19-targeting
+ vinca alkaloid
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05504291
Advanced
Phase 2
Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma (
ARET2121
)
alkylating agent
+ vinca alkaloid
Retinoblastoma
WA
6009 - Perth - Perth Children's Hospital
NCT05304585
Advanced
Phase 3
Recruiting
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma (
ARST2032
)
Cyclophosphamide
Dactinomycin
Radiotherapy
Vincristine
alkylating agent
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
vinca alkaloid
+ vinca alkaloid
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04884035
Haem
Phase 1
Recruiting
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma (
CC-220-DLBCL-001
)
CELMoD agent
cereblon modulator
+ vinca alkaloid
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
WA
6000 - Perth - Royal Perth Hospital (COMPLETED)
NCT04759586
Haem
Phase 3
Recruiting
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (
NCI-2021-01071
)
anti-PD-1 monoclonal antibody
+ vinca alkaloid
Diffuse large B-cell lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT04623541
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (
EPCORE™-CLL-1
)
bispecific T-cell engager,CD20-targeting
+ vinca alkaloid
Chronic lymphocytic leukaemia
Small Lymphocytic Lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
+ vinca alkaloid
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04322318
Advanced
Phase 2
Recruiting
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) (
AREN1921
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Radiotherapy
Topotecan
Vincristine
alkylating agent
anthracycline
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Wilms tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre (SUSPENDED)
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04221035
Advanced
Phase 3
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (
HR-NBL2
)
Busulfan
Carboplatin
Cisplatin
Cyclophosphamide
Dacarbazine
Dinutuximab
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Melphalan
Radiotherapy
Temozolomide
Thiotepa
Vincristine
alkylating agent
anthracycline
anti-GD2 monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT03959085
Haem
Phase 3
Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (
AALL1732
)
anti-CD22 antibody-drug conjugate
+ vinca alkaloid
Acute lymphoblastic leukaemia
Leukaemia
Lymphoma
Mixed phenotype acute leukaemia
NSW
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (SUSPENDED)
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12624000532505
Advanced
Phase 3
Recruiting
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (
INTER-EWING-1
)
Cyclophosphamide
Doxorubicin
Etoposide
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Ewing sarcoma
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12621001529831
Haem
Phase 2
Recruiting
NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL). (
PACIFIC
)
anti-PD-1 monoclonal antibody
+ vinca alkaloid
B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12619001656123
Haem
Phase 1
Not yet recruiting
Clarifying the role of early application of CAR T cells in Primary refractory and early relapsed diffuse large B cell lymphoma patients. (
CLARIFY-NHL34
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Fludarabine
Ifosfamide
Mesna
Prednisolone
Rituximab
Vincristine
alkylating agent
anthracycline
anti-CD20 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
sodium mercaptoethanesulfonate
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Diffuse large B-cell lymphoma
NCT06091865
Haem
Phase 3
Active not recruiting
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (
OLYMPIA-3
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
+ vinca alkaloid
Diffuse large B-cell lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4217 - Benowa - Pindara Private Hospital
NCT05578976
Haem
Phase 3
Active not recruiting
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (
EPCORE-DLBCL-2
)
bispecific T-cell engager,CD20-targeting
+ vinca alkaloid
Diffuse large B-cell lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Hollywood Private Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03188159
Advanced
Phase 2
Unknown
Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (VIP) (
GY01-05-16
)
vinca alkaloid
Fallopian tube cancer
Ovarian cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (16)
Active not recruiting (2)
Not yet recruiting (1)
Unknown (1)
Status unknown (1)
Recruitment Country and State
NSW (16)
VIC (15)
WA (14)
QLD (10)
SA (6)
NZ (6)
NT (1)
ACT (1)
TAS (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (2)
Phase 2 (4)
Phase 3 (12)
Trial Type
Haem (12)
Advanced (9)
Cancer Therapy Class
CD20
52%
cereblon
14%
BTK
10%
CD19
10%
CD79b
10%
PD-1
10%
PD-1/PD-L1
10%
KIT
10%
PDGFR
10%
VEGFR
10%
TF
5%
Trop2
5%
ERBB2
5%
BCL2
5%
GD2
5%
CD22
5%
FGFR
5%
FGFR1
5%
FGFR1/2/3
5%
FGFR2
5%
FGFR3
5%
FGFR4
5%
RET
5%
ALK
5%
ATR
5%
BCR-ABL1
5%
CDK4
5%
CDK6
5%
CRAF
5%
EGFR
5%
FLT3
5%
JAK1
5%
JAK2
5%
MET
5%
PDGFRA
5%
PI3K
5%
RAF
5%
ROS1
5%
SMO
5%
SRC
5%
YES1
5%
mTOR
5%
mTORC1
5%
mTORC2
5%
Facility
6009 - Perth - Perth Children's Hospital (6)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
2145 - Westmead - The Children's Hospital at Westmead (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (4)
2305 - New Lambton Heights - John Hunter Children's Hospital (4)
2170 - Liverpool - Liverpool Hospital (4)
3004 - Melbourne, Southbank - Alfred Health (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
3168 - Clayton - Monash Medical Centre (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
2031 - Randwick - Sydney Children's Hospital (3)
NZ.1023 - Grafton - Starship Children's Hospital (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
3052 - Parkville - Royal Children's Hospital Melbourne (3)
4101 - South Brisbane - Queensland Children's Hospital (3)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6000 - Perth - Royal Perth Hospital (2)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
3149 - Mount Waverley - Waverley Private Hospital - Oncology (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2217 - Kogarah - St George Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
2031 - Randwick - Prince of Wales Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2605 - Garran - The Canberra Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3066 - Epping - Northern Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3002 - East Melbourne - Epworth Freemasons (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
6005 - West Perth - Perth Blood Institute (1)
6009 - Nedlands - Hollywood Private Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Lymphoma
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Solid tumour
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Sarcoma
Leukaemia
Lymphoid leukaemia
Chronic lymphocytic leukaemia
Gynaecological cancer
Mantle cell lymphoma
Cervical cancer
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Breast adenocarcinoma
Breast cancer
HER2-positive breast cancer
Retinoblastoma
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
Soft tissue sarcoma
Small Lymphocytic Lymphoma
Wilms tumour
Neuroblastic tumour
Neuroblastoma
Neurological cancer
Peripheral nervous system tumour
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
Bone cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Fallopian tube cancer
Ovarian cancer
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy